Previous 10 | Next 10 |
NOVATO, Calif., March 09, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that Shalini Sharp, the company's Chief Financial Offi...
NOVATO, Calif. and TOKYO, Feb. 27, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare diseases, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: ...
NOVATO, Calif., Feb. 21, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that Tom Kassberg, the company’s Chief Business ...
Image source: The Motley Fool. Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) Q4 2019 Earnings Call Feb 13, 2020 , 5:00 p.m. ET Operator Continue reading
Ultragenyx Pharmaceutical Inc. (RARE) Q4 2019 Earnings Conference Call February 13, 2020 05:00 PM ET Company Participants Danielle Keatley - Senior Director of Investor Relations Emil Kakkis - Chief Executive Officer & President Shalini Sharp - Chief Financial Officer Conf...
Ultragenyx (NASDAQ: RARE ) Q4 results : More news on: Ultragenyx Pharmaceutical Inc., Healthcare stocks news, Earnings news and commentary, , Read more ...
Ultragenyx Pharmaceutical (NASDAQ: RARE ): Q4 GAAP EPS of -$1.62 misses by $0.26 . More news on: Ultragenyx Pharmaceutical Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
2019 total revenue is $103.7 million; 2019 Crysvita ® (burosumab) revenue to Ultragenyx is $87.3 million 2020 Crysvita revenue in Ultragenyx territories guidance of $125 million to $140 million reaffirmed NOVATO, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceut...
NOVATO, Calif., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Thursday, Februa...
Investment Thesis Notwithstanding two commercialized products and a rich pipeline, the twelve-month share price decline for Ultragenyx Pharmaceutical Inc. ( RARE ) had approached ~6.5% by early 2020 compared to ~12.0% LTM (last-twelve-month) gain in the NBI (NASDAQ Biotechnology Index). ...
News, Short Squeeze, Breakout and More Instantly...
Ultragenyx Pharmaceutical Inc. Company Name:
RARE Stock Symbol:
NASDAQ Market:
Ultragenyx Pharmaceutical Inc. Website:
NOVATO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5...
NOVATO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the company will share the latest clinical data, regulatory progress and program next steps for GTX-102, its investigational antisense oligonucleotide for Angelman syndrome, on Wed...
2024-07-24 04:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...